Knockdown of FAXDC2 promotes cell proliferation, migration, invasion and EMT in HepG2 cells by upregulating c-Met and...

Hepatocellular carcinoma (HCC) is one of the most common malignant diseases with high morbidity and mortality rates, and the lack of effective therapeutic targets limits the clinical treatment efficacy. Fatty acid hydroxylase domain containing 2 (FAXDC2) regulates the synthesis of cholesterol and sphingomyelin and promotes cancer development in various types of cancer. However, the role and mechanism of FAXDC2 on HCC still remained to be clarified.

TCGA-LIHC database was utilized to identify the expression of FAXDC2 and its effect on the prognosis in HCC patients. The efficiency of FAXDC2 knockdown interfered by siRNA in HepG2 cells was detected by western blot and qPCR. CCK-8, colony formation, transwell migration and invasion assays were used to evaluate the functions of FAXDC2 on cell proliferation, migration and invasion in HepG2 cells. Western blot and qPCR were applied to examine the expression of epithelial-mesenchymal trasnsition (EMT)-related markers and c-Met signaling pathway. Furthermore, c-Met knockdown by siRNA and c-Met activity inhibition by Tepotinib were used to explore the regulatory relationship between FAXDC2 and c-Met in HCC cells.

The FAXDC2 mRNA level was downregulated in the liver tissues of HCC patients and its expression was significantly correlated with clinical stage. The lower FAXDC2 expression in the HCC patients was associated with a poor prognosis. FAXDC2 knockdown promoted cell proliferation, migration, invasion, and EMT in HepG2 cells. Interestingly, we found that FAXDC2 knockdown not only upregulated the expression of c-Met, but promoted its phosphorylation. Above all, both knockdown of c-Met and Tepotinib-mediated c-Met activity inhibition significantly counteracted cell proliferation, migration, invasion, and EMT of HepG2 cells caused by knocking down FAXDC2.

FAXDC2 acts as a tumor suppressor in HCC, and its knockdown promotes cell proliferation, migration, invasion, and EMT via upregulating c-Met expression and enhancing its phosphorylation in HepG2 cells. Therefore, the FAXDC2/c-Met axis may serve as a noval potential therapeutic target for HCC intervention.